J&J said July 30 that it has begun its first human trials of its experimental COVID-19 vaccine.
The company launched human trials in Belgium and the U.S. after an early trial showed its vaccine helped protect a group of primates from COVID-19 infection after a single dose.
In the primate study, all the animals given the vaccine and exposed to COVID-19 six weeks later were immune except for one, which had only low levels of the virus.
J&J’s ability to produce an immune response in a single dose may give it an advantage over other drugmakers rolling out vaccines that took two doses to elicit an immune response.
J&J said it’s looking to begin the last phase of testing in September in a trial of over 1,000 people. It’s ramping up production to try to provide over 1 billion doses to people around the world, the drugmaker said, but did not say how much it will charge for the vaccine.
Read the full news release here.
More articles on pharmacy:
Moderna proposes coronavirus vaccine will cost $50 to $60 per course
US sending Texas hospitals 500 cases of remdesivir as COVID-19 cases surge
Operation Warp Speed: a timeline so far
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.